Accepted Manuscript

Commentary

Tanovea® for the treatment of lymphoma in dogs

Erik De Clercq

PII: S0006-2952(18)30195-3

DOI: https://doi.org/10.1016/j.bcp.2018.05.010

Reference: BCP 13145

To appear in: Biochemical Pharmacology

Received Date: 13 April 2018 Accepted Date: 15 May 2018



Please cite this article as: E. De Clercq, Tanovea® for the treatment of lymphoma in dogs, *Biochemical Pharmacology* (2018), doi: https://doi.org/10.1016/j.bcp.2018.05.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Commentary

Tanovea® for the treatment of lymphoma in dogs

Erik De Clercq*

KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research,

Herestraat 49, 3000 Leuven, Belgium

*Tel + 32 16 379020

E-mail address: erik.declercq@kuleuven.be

Download English Version:

https://daneshyari.com/en/article/8523805

Download Persian Version:

https://daneshyari.com/article/8523805

<u>Daneshyari.com</u>